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Abstract: Aggressive cancer cells are characterized by their capacity to proliferate indefinitely and to
propagate a heterogeneous tumor comprised of subpopulations with varying degrees of metastatic
propensity and drug resistance properties. Particularly daunting is the challenge we face in the
field of oncology of effectively targeting heterogeneous tumor cells expressing a variety of markers,
especially those associated with a stem cell phenotype. This dilemma is especially relevant in
breast cancer, where therapy is based on traditional classification schemes, including histological
criteria, differentiation status, and classical receptor markers. However, not all patients respond in a
similar manner to standard-of-care therapy, thereby necessitating the need to identify and evaluate
novel biomarkers associated with the difficult-to-target stem cell phenotype and drug resistance.
Findings related to the convergence of embryonic and tumorigenic signaling pathways have identified
the embryonic morphogen Nodal as a promising new oncofetal target that is reactivated only in
aggressive cancers, but not in normal tissues. The work presented in this paper confirms previous
studies demonstrating the importance of Nodal as a cancer stem cell molecule associated with
aggressive breast cancer, and advances the field by providing new findings showing that Nodal is
not targeted by standard-of-care therapy in breast cancer patients. Most noteworthy is the linkage
found between Nodal expression and the drug resistance marker ATP-binding cassette member 1
(ABCA1), which may provide new insights into developing combinatorial approaches to overcome
drug resistance and disease recurrence.
Keywords: Nodal; breast cancer; ABCA1; cancer stem cells; doxorubicin/cyclophosphamide/taxanes
(paclitaxel or docetaxel) (ACT); docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP);
docetaxel/cyclophosphamide (TC)
Cancers 2019, 11, 340; doi:10.3390/cancers11030340 www.mdpi.com/journal/cancers
Cancers 2019, 11, 340 2 of 11
1. Introduction
Decades’ worth of research has sought to define the various stages of breast cancer
progression with the overall goal of improving the prediction of disease outcome. From a
traditional perspective, the diagnosis of breast cancer has relied heavily on histological criteria [1].
In addition, the Nottingham grading system has specified key architectural features that further
define invasive breast cancer and are critical to classifying the differentiation status, with a poorly
differentiated phenotype being the hallmark of more aggressive disease [2]. Fortunately, advances in
molecular medicine have revealed critical markers, such as estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (Her2), and these have been especially
helpful in further classifying certain types of breast cancers into distinctive functional groups [3],
in addition to informing selection of patients for specific targeted treatment options [4,5].
Poorly differentiated, aggressive breast cancer cells have been shown to possess stem cell
properties, proliferate indefinitely, and propagate a tumor comprised of heterogeneous cell
subpopulations with varying degrees of drug resistance and metastatic properties [6]. One of
the most daunting challenges we face in the oncological sciences is developing the most effective
targeting of these heterogeneous tumors containing breast cancer cells expressing various markers,
especially those associated with stem cells, for which targeted therapies are currently under
development. Particularly noteworthy is the phenotype associated with aggressive triple-negative
breast cancer (TNBC), which exhibits little-to-no expression of classical markers, and patients are at
significantly higher risk of relapsing with metastatic disease following treatment with standard-of-care
therapies. Thus, there is a critical need to identify novel targetable molecules that can enhance current
therapies by mitigating the stem cell phenotype of aggressive breast cancer and concurrently reversing
drug resistance.
Tumor cell plasticity underlies the stem cell phenotype. Indeed, our basic understanding of
the functional properties associated with this phenotype has been significantly advanced by the
molecular analyses of aggressive breast cancer cells compared with nonaggressive breast cancer [7,8].
Particularly noteworthy for the aggressive phenotype is the co-expression of multiple cell type-specific
markers normally associated with endothelial cells, mesenchymal cells, and stem cells, concomitant
with the downregulation of E-cadherin, ER, and PR [6]. Further functional analyses have uncovered
selective advantages associated with this plastic phenotype pertinent to tumorigenesis, metastasis,
and drug resistance, including epithelial-to-mesenchymal transition (EMT), vasculogenic mimicry
(VM), and unregulated growth potential via the reactivation of the Nodal signaling pathway [9–11].
Due to Nodal’s quintessential role as a highly influential morphogen during critical phases
of embryogenesis, together with the concept that tumorigenesis recapitulates many developmental
events, our laboratory has focused attention on the implications of Nodal’s re-emergence in aggressive
forms of cancer. From developmental biology studies, we know that Nodal is a member of the
transforming growth factor-β (TGFβ) superfamily [12], and orchestrates the coordination of body axis
formation, left-right patterning, the maintenance of human embryonic stem cell (hESC) pluripotency,
and activation of EMT [12]. Nodal signals via binding to Cripto-1/ALK4/7/ActRIIB receptor complex,
leading to the phosphorylation of Smad2/Smad3 followed by association with Smad4, and subsequent
translocation to the nucleus [13]. Nodal expression in humans is largely restricted to embryonic tissues
and is generally absent in normal adult tissues, rendering it a promising target specific to cancer.
Based on Nodal’s critical role in sustaining the pluripotent phenotype of hESCs, we have hypothesized
that it serves as a master plasticity gene in cancer, and have validated its expression as a cancer
stem cell (CSC) signaling molecule with significant promise as a new target in aggressive forms of
cancer [6,14,15]. In this regard, our laboratory and others have shown that Nodal expression underlies
unregulated growth, tumorigenicity, and metastasis [11,12,14,16,17], and in terms of Nodal-positive,
metastatic breast cancer, we and others have observed the concurrent expression of several stem cell
markers, including CD44, ALDH1, Notch, Oct4, CD133, Sox2, and Nanog [18,19]. Furthermore, there is
a correlation between a high level of Nodal expression and the expression of CD44 and lower overall
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survival of breast cancer patients [19]. The current paper focuses on the significance of Nodal expression
in breast cancer patients who have undergone surgical intervention and standard-of-care therapy,
and provides new insights into the association of this CSC molecule and drug resistance.
2. Results and Discussion
A previous, noteworthy breast cancer study from our laboratory focused on Nodal localization
in 431 therapeutically naïve patients diagnosed with benign or malignant disease and revealed a
potential role for Nodal as a new prognostic biomarker for disease progression when compared with
currently used reference markers [16]. Specifically, the intensity of Nodal immunohistochemistry
(IHC) staining was significantly stronger in undifferentiated, advanced stage invasive breast cancer
compared with early stage breast disease. Treatment of human breast cancer cells in vitro with a
Nodal blocking antibody results in reduced proliferation and diminished colony-forming ability.
Experimental knockdown of Nodal in in vivo models of TNBC also results in significantly reduced
levels of tumorigenesis [19]. These findings prompted the translationally relevant question whether
Nodal is targeted by standard-of-care therapy in breast cancer patients. Based on the observations
derived from our previous studies in melanoma patients and related animal models—where treatment
with conventional dacarbazine or BRAF inhibitors did not diminish Nodal expression [14,17]—we
postulated that Nodal would remain before and after standard-of-care therapy in breast cancer patients.
2.1. Nodal is Associated with Disease Progression
Tissue sections from 14 patients determined to have ductal carcinoma of the breast were studied
before and after neoadjuvant therapy using IHC to evaluate Nodal expression, using a previously
established scoring index [16]. Patient clinical characteristics are presented in Tables 1 and 2,
including the patients’ age; histological description; grade; clinical and pathological stage; original and
post-therapy tumor size; status of ER, PR, Her2/neu, and Ki67; lymph node involvement before
and after therapy; neoadjuvant standard-of-care therapy; surgical intervention; distant recurrence;
years since diagnosis; and IHC scores for Nodal pre- and post-treatment. The Nodal IHC analysis
of these patients’ tumors, pre- and post-treatment with current standard-of-care therapy
(doxorubicin/cyclophosphamide/taxanes (ACT), docetaxel/carboplatin/trastuzumab/pertuzumab
(TCHP) and docetaxel/cyclophosphamide (TC)), is presented as a graph in Figure 1 showing the
percent of the tumor that expresses Nodal relevant to the therapeutic treatment. In all cases, Nodal is
expressed before and after treatment and, in the majority of cases, Nodal expression is enhanced
post-treatment. Although a power assessment is not possible to achieve with this small sample number,
the data shown support the hypothesis that Nodal is not abrogated by standard-of-care therapy.
Nodal IHC staining is presented in Figure 2 in three patients’ tumors, where Nodal expression appears
enhanced following treatment with ACT, TCHP, or TC. Further analysis suggests that there might be
an increase in lymph node involvement with enhanced Nodal expression and supports the need for
further studies to identify if there is a correlation between Nodal expression and disease progression
in a larger patient cohort.
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Table 1. Specific diagnoses, clinical measurements, treatment regimens, and observations for the breast cancer patients’ tumors, with incomplete pathological
responses, examined in this study.
Subject
Number
Age at
Diagnosis
(years)
Histology Grade ER% PR% Her2/neu Ki67 Clinical Stage OriginalTumor Size
* Lymph Node
Involvement
Pre-Therapy
Pathologic
Stage
SH-02 53 Ductal 3 0 0 1 56 IIA 2.8 N0 I
SH-04 69 Ductal 2 99 22 1 33 IIIB 4.9 N1 IIA
SH-05 67 Ductal 2 100 100 1 13 IIIB 5.1 N1 IIIB
SH-08 32 Ductal 3 0 0 1 86 IIB 5.1 N0 I
SH-09 56 Ductal 2 100 62 2 negatives FISH 24 IIB 2.7 N1 IIA
SH-10 45 Ductal 2 99 96 1 31 IIA 1.8 N1 IIA
SH-11 58 Ductal 3 0 0 3 97 IIB 2.4 N1 IIB
SH-12 45 Ductal 3 95 88 2 positives FISH 74 IIA 3.3 N1 I
SH-13 53 Ductal 3 0 0 1 90 IIIA 2.6 N2 IIA
SH-14 57 Ductal 2 100 100 1 43 IIIC 2.8 N3 IIB
SH-15 59 Ductal 2 100 34 1 25 III 3.5 N1 IIIC
SH-17 61 Ductal 3 5 0 1 89 IIB 3.4 N1 I
SH-19 59 Ductal 3 22 0 1 96 IIB 3.7 N1 IIA
SH-20 42 Ductal 3 5 3 1 ND IIB 2.6 N1 IIIC
* Lymph node status categories. N0: Axillary and other nearby lymph nodes do not have cancer or only have isolated tumor cells (individual cancer cells), when examined under a
microscope; N1: Micrometastases (very small clusters of cancer cells), or 1–3 axillary lymph nodes have cancer, and/or internal mammary nodes have cancer or micrometastases found on
sentinel node biopsy; N2: 4–9 axillary lymph nodes have cancer, or internal mammary nodes have cancer, but axillary lymph nodes do not have cancer; N3: 10 or more axillary lymph
nodes have cancer, or infraclavicular (under the clavicle) nodes have cancer, or internal mammary nodes have cancer plus 1, or more axillary lymph nodes have cancer, or 4 or more
axillary lymph nodes have cancer plus internal mammary nodes have cancer, or micrometastases found on sentinel node biopsy, or supraclavicular (above the clavicle) nodes have cancer.
ER: estrogen receptor; PR: progesterone.
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Table 2. Specific diagnoses, clinical measurements, treatment regimens and observations for the breast cancer patients’ tumors, with incomplete pathological responses,
examined in this study.
Subject
Number
† %Nodal
Expression in
Tumor Pre-
Treatment
† %Nodal
Expression in
Tumor Post-
Treatment
† %ABCA1
Expression in
Tumor Pre-
Treatment
† %ABCA1
Expression in
Tumor Post-
Treatment
Post-Therapy
Tumor Size
* Lymph Node
Involvement
after Therapy
Neo-Adjuvant
Therapy
(Drug Regiment)
Surgical Intervention DistantRecurrence
Years Since
Diagnosis
SH-02 25% 95% 30% 80% 0.9 N0 ACx4;Tx12 Lump and SLN No 2
SH-04 95% 90% 50% 80% 2.4 N0 ACx4;Tx10 Mastectomy and ALND No 1
SH-05 50% 95% 25% 80% 5 N1 TC x 4 Mastectomy and ALND No 2
SH-08 90% 40% 0% 75% 0.6 N0 ACx4;Tx12 Mastectomy and SLN No 2
SH-09 95% 75% 95% 95% 0.5 N1 ACx4;Tx12 Mastectomy and ALND No 3
SH-10 90% 95% 90% 80% 1.5 N1 ACx4;Tx12 Central lumpectomy andSLN No 1
SH-11 90% 95% 10% 60% 1.9 N1 TCHP Lump and SLN No 1
SH-12 95% 90% 10% 80% 0.7 N0 TCHP Lump and SLN No 1
SH-13 10% 95% 75% 40% 2.2 N1 ACx4;Tx12 Lump and ALND No 1
SH-14 75% 90% 20% 20% 2.8 N1 TCx4 Mastectomy and ALND No 2
SH-15 95% 95% 20% 95% 2.2 N3 ACx4;Tx12 Mastectomy and ALND No 1
SH-17 80% 75% 80% 80% 1.4 N0 ACx4;Tx12 Lump and SLN Yes 2
SH-19 50% 90% 10% 90% 2.6 N0 ACx4;Tx2 Lump and ALND No 1
SH-20 75% 80% 10% 50% 6.3 N3 TCx6 Mastectomy and ALND Yes 2
* Lymph node status categories. N0: Axillary and other nearby lymph nodes do not have cancer or only have isolated tumor cells (individual cancer cells), when examined under a
microscope; N1: Micrometastases (very small clusters of cancer, or 1–3 axillary lymph nodes have cancer, and/or internal mammary nodes have cancer or micrometastases found on
sentinel node biopsy; N2: 4–9 axillary lymph nodes have cancer, or internal mammary nodes have cancer, but axillary lymph nodes do not have cancer; N3: 10 or more axillary lymph
nodes have cancer, or infraclavicular (under the clavicle) nodes have cancer, or internal mammary nodes have cancer plus 1, or more axillary lymph nodes have cancer, or 4 or more
axillary lymph nodes have cancer plus internal mammary nodes have cancer, or micrometastases found on sentinel node biopsy, or supraclavicular (above the clavicle) nodes have cancer;
† %Nodal (or † %ATP-binding cassette member 1 (ABCA1)) in the tumor is relative to Nodal (or ABCA1) measured in the entire tumor, where 100% represents every tumor cell expressing
Nodal (or ABCA1). ACT: (doxorubicin/cyclophosphamide/taxanes; TCHP: docetaxel/carboplatin/trastuzumab/pertuzumab; TC: docetaxel/cyclophosphamide; SLN: sentinel lymph
node; ALND: ancillary lymph node dissection.
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with  current  standard‐of‐care  therapy  (ACT, TCHP, and TC), were  examined  for  the presence of 
Nodal  protein  by  immunohistochemistry.  The  results  are  presented  as  a  graph  representing  the 
percent of  the  tumor(s)  that expresses Nodal categorized by  the  therapeutic  treatment. Percent of 
tumor expressing Nodal  is relative to Nodal measured  in the entire tumor where 100% represents 
every tumor cell expressing Nodal. 
 
Figure 2. The presence of the Nodal protein (brown color)  in breast cancer patient tumor sections, 
pre‐  and  post‐current‐standard‐of‐care‐treatments  (ACT,  TCHP,  and  TC),  was  examined  by 
immunohistochemical  staining  with  IgG  used  as  a  control  for  non‐specific  staining  (20×  original 
magnification). Bar graphs below the  immunohistochemistry (IHC) data depict the percent of tumor 
positive for Nodal pre‐ and post‐therapy (relative to where 100% represents every tumor cell expressing 
Nodal) correlated with the lymph node status categories N0–N3 (see Table 1 and Table 2 legends). 
Figure 1. Clinically derived tissue sections fro breast cancer patients, both pre- and post-treatment
with current standard-of-care therapy (ACT, TCHP, and TC), were examined for the presence of
Nodal protein by immunohistochemistry. The results are presented as a graph representing the percent
of the tumor(s) that expresses Nodal categorized by the therapeutic treatment. Percent of tumor
expressing Nodal is relative to Nodal measured in the entire tumor where 100% represents every tumor
cell expressing Nodal.
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Figure 2. The presence of the Nodal protein (brown color) in breast c ncer patient tumor sections, pre- and
post-current-standard-of-care-treatments (ACT, TCHP, and TC), was examined by immunohistochemical
staining with IgG used as a control for non-specific staining (20× original magnification). Bar graphs below
the immunohistochemistry (IHC) data depict the percent of tumor positive for Nodal pre- and post-therapy
(relative to where 100% represents every tumor cell expressing Nodal) correlated with the lymph node status
categories N0–N3 (see Tables 1 and 2 legends).
While there is a statistically significant decrease in the tumor size in response to the
different standard-of-care treatments (ACT, TCHP and TC; Figure 3A; p = 0.015), there is a
statistically insignificant change in the percent of Nodal in the tumors after the different treatments
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(Figure 3B; p = 0.27). These observations suggest that while these standard-of-care treatments do kill
some cells in the tumor population, there appears to be a subpopulation of tumor cells that is drug
resistant and expresses Nodal.
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as a CSC signaling molecule and is only expressed by subpopulations within a heterogeneous tumor, 
Figure 3. The standard-of-care treatments used in the study (ACT, TCHP, and TC) decreased the
size of the tumors but did not change the percent of Nodal in the tumors. (A) There is a statistically
significant decrease in the tumor size in response to the different standard-of-care treatments (p = 0.015,
Wilcoxon signed-rank test); while (B) there is a statistically insignificant change in the percent of Nodal
in the tumors after treatment (p = 0.27, Wilcoxon signed-rank test).
2.2. Nodal is Associated with Drug Resistance
In previous melanoma studies, we observed an association between Nodal expression and the
drug resistance marker ABCA1 [20]. Most noteworthy, a direct correlation was demonstrated when
Nodal expression was downregulated, resulting in the complete mitigation of ABCA1. These data
provided the first direct evidence linking the CSC signaling molecule Nodal and drug resistance,
which provided new insights into the possible mechanisms underlying Nodal’s significance in
aggressive cancer. We extended these observations to the current breast cancer study where,
using tissue sections from the same patients’ tumors shown in Figure 2 for Nodal staining and lymph
node involvement, we performed IHC localization for ABCA1, as presented in Figure 4. The IHC
staining pattern for ABCA1 is particularly noteworthy in the post-treatment samples for ACT, TCHP,
and TC therapy, and may provide new clues linking patient responsiveness relevant to these therapies.
Furthermore, sections from these same samples were also dual stained for both Nodal and ABCA1
and cells identified which stain for both Nodal and ABCA1 (Supplemental Figure S1).
The ABCA1 protein is an ATP-binding cassette transporter which functions as a cholesterol
efflux pump in the cellular lipid removal pathway and acts as the primary gatekeeper for eliminating
tissue cholesterol [21]. Interestingly, ABCA1 has been shown to be upregulated in drug resistance to
curcumin in melanoma [22], doxorubicin resistance in breast cancer and hepatocellular carcinoma [23,24],
paclitaxel and carboplatin resistance in serous epithelial ovarian cancer [25], and cisplatin resistance in
non-small-cell lung and epidermoid carcinomas [26]. Particularly noteworthy is the Kaplan–Meier plot
for ABCA1 low and high expression in breast cancer patient tumors—documented in the National Center
for Biotechnology Information (NCBI), USA National Library of Medicine database, which shows a
significantly better survival probability for patients expressing low levels of ABCA1 in their breast cancer
compared with those who have a high expression [27].
Collectively, these observations—showing a connection between Nodal’s presence in aggressive
breast cancer, before and after standard-of-care therapy, with a possible association with the ABCA1
drug resistance marker—provide preliminary evidence for pursuing in more depth. Since Nodal
acts as a CSC signaling molecule and is only expressed by subpopulations within a heterogeneous
tumor, our body of experimental data supports a future therapeutic approach using standard-of-care
therapy in a combinatorial manner with anti-Nodal therapy. We have tested this approach in three
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experimental TNBC models expressing high levels of Nodal, where treatment with doxorubicin
did not effectively diminish the Nodal target [11]. However, sequential treatment of the TNBC
models with doxorubicin, followed by anti-Nodal antibody regimen, resulted in significant decreases
in cellular growth and viability. This study further revealed that anti-Nodal antibody treatment,
following doxorubicin, affects the cellular stress (p38) and repair (ChK1) pathways. These findings
support a unique approach in inhibiting Nodal, thereby disrupting the cancer cell’s ability to repair
their compromised DNA following front-line therapy. Additional studies focused on Nodal’s role in
drug resistance are warranted to better predict patients’ responsiveness to standard-of-care therapy.
3. Materials and Methods
3.1. Breast Cancer Patient Samples
Archival formalin-fixed and paraffin-embedded breast tissue sections from 14 patients diagnosed
with ductal breast cancer (with varying ER, PR status, and Her2 expression) were matched relevant to
pre- and post-treatment with standard-of-care therapy (ACT, TCHP, or TC), and obtained from the
Betty Puskar Breast Care Center, Morgantown, West Virginia. Patient tumor sections were de-identified
and labeled with numerical codes in accordance with the approved West Virginia University expedited
IRB protocol (#1705572966R00) for using de-identified patient samples for research.
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Figure 4. The presence of the ABCA1 protein (brown color) in breast cancer patient tumor sections, pre- and
post-current-standard-of-care-treatments (ACT, TCHP, and TC) was examined by immunohistochemical
staining with IgG used as a control for non-specific staining (20× original magnification).
3.2. Immunohistochemistry
Four-micron-thick, formalin-fixed, paraffin-embedded tissue sections were prepared and
immunohistochemistry was carried out on a DAKO AutostainerPlus (AgilentTechnologies Inc.,
Santa Clara, CA, USA), s previously described [14]. Briefly, following antigen retrieval and
blocking steps, sections were incubated with a mouse anti-human Nodal antibody (Abcam, ab55676,
1:300; Cambridge, MA, USA) or rabbit ABCA1 antibody (Novus Biologicals, NB400-105,
1:200; Centennial, CO, USA) for 60 min, followed by biotinylated anti-mouse or anti-rabbit
secondary antibody, respectively (GM601 and GM608, Biocare Medical, LLC, Concord, CA, USA).
The sections were then treated with streptavidin peroxidase (TS125HR, Thermo Scientific Lab Vision,
Fremont, CA, USA) and a brown color developed with 3,3′-diaminobenzidine substrate (TA125QHDX,
Thermo Scientific Lab Vision). The sections were then counterstained with hematoxylin (NM-HEM,
Biocare Medical, LLC). As a negative control, adjacent serial sections were incubated with ChromPure
mouse IgG and ChromPure rabbit IgG (015-000-003 and 011-000-003, Jackson Immunoresearch Labs,
West Grove, PA, USA) at the same concentration as the primary antibodies. Staining for Nodal and
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ABCA1 were analyzed and scored blinded with respect to clinical information. Dual staining of the
tissue sections with anti-Nodal and anti-ABCA1 antibodies was performed using the MACH 2 Double
Stain 2 reagent according to the manufacturer’s protocols (Biocare Medical, MRCT525) with the Warp
Red Chromogen kit (WR806) for red color.
3.3. Statistical Analyses and Clinical Correlations
Descriptive statistics were used to summarize data, including frequency distribution and
percentage for categorical variables and mean with standard deviation for continuous variables.
Bar plots and waterfall plots were used to demonstrate the data before and after treatment (Figure 3A,B).
In the correlative analysis between treatment and clinical outcomes, Wilcoxon signed-rank test
was used to assess the change of Nodal staining and tumor size for the paired data before and
after treatment.
4. Conclusions
In aggressive breast cancer, where a lack of targetable molecules exists, together with the
likelihood for relapse following chemotherapy, additional studies are needed to evaluate novel
biomarkers associated with disease progression and drug resistance. Our discovery of the reactivation
of the Nodal signaling pathway in cancer has provided new insights—and instigated additional
questions—into the linkage that appears to exist among the CSC phenotype, disease progression,
and drug resistance, which can inform the design of more effective clinical trials. Indeed, targeting CSCs
and their metastatic niches presents new therapeutic opportunities worth pursuing based on an
accumulating body of evidence [28,29].
We recognize that normal progenitor cells and CSCs use similar signaling pathways to sustain
growth. Moreover, findings related to the convergence of embryonic and tumorigenic signaling
pathways have illuminated the significance of oncofetal targets that are strictly regulated during normal
development but aberrantly reactivated in aggressive forms of cancer [18,30]. Particularly noteworthy
are oncofetal targets, such as Nodal, that re-emerge only in aggressive cancers but not in normal tissues.
The work presented in this paper confirms previous studies showing the importance of Nodal as
a CSC molecule associated with aggressive breast cancer, and advances the field by providing new
findings indicating that Nodal is not targeted by standard-of-care therapy in breast cancer patients.
Most noteworthy is the linkage between Nodal expression and the drug resistance marker ABCA1.
Although the results are based on a small sample number, the preliminary findings are of special
interest in the design of new therapeutic strategies that target the stem cell properties of adult cancer
cells, especially as part of a combinatorial approach to overcome drug resistance and disease recurrence.
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Figure S1: Breast cancer patient tumor sections, pre- and post-current standard-of-care-treatments (ACT, TCHP
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